• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

SCOPE Data Update: 11 December 2025

Dec 12, 2025

Select the category

  • All categories
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1
  • Covid-19

Select the year

  • All years
  • 2024
  • 2023
  • 2022
Clear Filters
U

*PDF*Annual Meeting of The American Association for Cancer Research (AACR), 14 – 19 April 2023 in Orlando, Florida, USA

April 18, 2023

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Association for Cancer Research Annual Meeting

April 18, 2023

Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool

April 17, 2023

Block Listing Application to AIM

April 17, 2023

Scancell Statement re: Silicon Valley Bank (SVB)

March 13, 2023

Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial

February 21, 2023

Scancell announces positive response in COVIDITY trial

February 13, 2023

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

February 1, 2023

Interim Results for the 6 months ended 31 October 2022

January 25, 2023

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy

December 9, 2022

Result of Annual General Meeting

November 23, 2022

14th Annual Meeting of the Protein & Antibody Engineering Summit (PEGS), 14-16 November 2022 in Barcelona, Spain

November 16, 2022
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 5
No results found.

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    About Us
    Leadership Team
    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy